Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Lasorella is active.

Publication


Featured researches published by Anna Lasorella.


Pediatric Radiology | 1998

Diagnostic imaging of primitive neuroectodermal tumour of the chest wall (Askin tumour)

G. Sallustio; Tommaso Pirronti; Anna Lasorella; Luigi Natale; Antonio Bray; Pasquale Marano

Objectives. To describe the radiological features of primitive neuroectodermal tumour (PNET) of the chest wall (Askin tumour) at diagnosis and to analyse the radiological changes occurring as a consequence of treatment and during follow-up. Materials and methods. Nine children with histologically proven PNET were studied. At diagnosis, all patients underwent chest X-ray (CXR), chest CT and bone scintigraphy; three patients also had MR and three had US. During treatment and follow-up, CT was performed in all patients. Results. CT demonstrated a solid heterogeneous chest wall mass in all children at diagnosis and six had a rib lesion. Small nodular densities in the extra-pleural fat were identified in three patients at diagnosis. US, performed in three patients, excluded tumour infiltration of the lung or diaphragm, which had been suspected on CT. On MR, the lesions showed high signal intensity in T1-weighted/proton-density images and intermediate/high signal intensity in T2-weighted images compared with muscle. Minimal chest wall involvement was demonstrated in one case by MRI. Extensive necrosis of tumour mass with pseudo-cystic appearance was documented in the five patients who underwent chemotherapy. Macroscopically complete resection was performed in five patients but there was early local recurrence after surgery in two, identified by CT in one and by MR in the other. Conclusions. PNET of the chest wall should be considered in a child with a chest wall mass. CT is valuable for evaluating tumour extension at diagnosis, the effects of chemotherapy and assessing tumour recurrence after surgery. However, CT can overestimate pleural, lung or diaphragmatic infiltration, which are better evaluated by US. MR was superior to CT in the evaluation of tumour extension in one of three patients and may be considered complementary to CT, particularly in very large chest wall tumours.


Pediatric Hematology and Oncology | 1986

Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.

Riccardo Riccardi; Frank M. Balis; Pietro Ferrara; Anna Lasorella; David G. Poplack; Renato Mastrangelo

Plasma levels of 6-mercaptopurine (6-MP) were measured after oral administration in 17 children with acute lymphoblastic leukemia (ALL). In the fasting state or after a breakfast consisting of 250 ml milk and 50 g biscuits, 6-MP was administered at a dose of 75 mg/m2. In patients studied in a fasting state, the mean time to plasma peak (tmax) level was 1.2 h, whereas in patient studied after breakfast the mean tmax was 2.3 h. This difference is statistically significant (p less than 0.001). Moreover, the 6-MP peak plasma concentration (cmax) and the areas under the plasma concentration time curves (AUC) were significantly reduced when the drug was administered after breakfast. The mean Cmax +/- SD were 0.98 +/- 0.54 microM and 0.63 +/- 0.48 microM, respectively (p less than 0.05). The mean 6-MP AUC +/- SD in patients studied in a fasting state and after breakfast were 143 +/- 69 microM min and 105 +/- 68 microM, respectively (p less than 0.01). These results indicated that 6-MP should be taken in a fasting state to optimize drug absorption in children undergoing chemotherapy for ALL.


Cancer Chemotherapy and Pharmacology | 1994

CLINICAL PHARMACOKINETICS OF CARBOPLATIN IN CHILDREN

Riccardo Riccardi; Anna Riccardi; Anna Lasorella; C Dirocco; Giovanni Carelli; Assunta Tornesello; Tiziana Servidei; A Iavarone; Renato Mastrangelo

The present study was undertaken to evaluate in children the plasma pharmacokinetics of free carboplatin given at different doses and schedules and to evaluate the inter- and intrapatient variability and the possible influence of schedule on drug exposure. A total of 35 children (age range, 1–17 years) with malignant tumors were studied. All patients had normal renal function (creatinine clearance corrected for surface body area, above 70 ml min−1 m−2; range, 71–151 ml min−1 m−2) and none had renal involvement by malignancy. Carboplatin was given at the following doses and schedules: 175, 400, 500, and 600 mg/m2 given as a 1-h infusion; 1,200 mg/m2 divided into equal doses and infused over 1 h on 2 consecutive days; and 875 and 1,200 mg/m2 given as a 5-day continuous infusion. A total of 57 courses were studied. Carboplatin levels in plasma ultrafiltrate (UF) samples were measured both by high-performance liquid chromatography and by atomic absorption spectrophotometry. Following a 1-h infusion, carboplatin free plasma levels decayed biphasically; the disappearance half-lives, total body clearance, and apparent volume of distribution were similar for different doses. In children with normal renal function as defined by creatinemia and blood urea nitrogen (BUN) and creatinine clearance, we found at each dose studied a limited interpatient variability of the peak plasma concentration (Cmax) and the area under the concentration-time curve (AUC) and a linear correlation between the dose and both Cmax (r=0.95) and AUC (r=0.97). The mean value ± SD for the dose-normalized AUC was 13±2 min m2 l−1 (n=57). The administration schedule does not seem to influence drug exposure, since prolonged i.v. infusion or bolus administration of 1,200 mg/m2 achieved a similar AUC (13.78±2.90 and 15.05±1.44 mg ml−1 min, respectively). In the nine children studied during subsequent courses a limited interpatient variability was observed and no correlation (r=0.035) was found between AUC and subsequent courses by a multivariate analysis of dose, AUC, and course number. The pharmacokinetic parameters were similar to those previously reported in adults; however, a weak correlation (r=0.52,P=0.03) between carboplatin total body clearance and creatinine clearance varying within the normal range was observed. A dosing formula appears unnecessary in children with normal renal function since a generally well-predictable free carboplatin AUC is achieved following a given dose.


Journal of Neuro-oncology | 2002

Hypersensitivity reactions to carboplatin in children.

Ilaria Lazzareschi; Antonio Ruggiero; Riccardo Riccardi; Giorgio Attinà; Cesare Colosimo; Anna Lasorella

Hypersensitivity reactions to carboplatin are rare but sometimes life-threatening events may occur requiring discontinuation of treatment. In our study, we describe clinical features and diagnostic procedures of carboplatin-associated reactions in children affected by low-grade astrocytoma and treated with multiple courses of carboplatin. In 6 out of 29 children, we reported allergic events.We also report a desensitization protocol for carboplatin administration, which allowed the patients to receive effective treatment without adverse reactions.


Journal of Chromatography B: Biomedical Sciences and Applications | 1989

High-performance liquid chromatographic assay for cytosine arabinoside and uracil arabinoside in cerebrospinal fluid and plasma

Anna Riccardi; Tiziana Servidei; Anna Lasorella; auRiccardo Riccardi

This paper describes an isocratic, reversed-phase HPLC technique that is simple, sensitive and relatively rapid. Using this method we performed pharmacokinetic studies on cerebrospinal fluid (CSF) and plasma of patients underdoing both conventional and high-dose chemotherapy with ara-C


Archive | 1987

Factors affecting the clinical pharmacology of antileukemic drugs

Riccardo Riccardi; Anna Lasorella; Renato Mastrangelo

In children with newly-diagnosed acute lymphoblastic leukemia (ALL) the current cure rate is approximately 50%. These results are obtained using multiple agent chemotherapy in conjunction with some form of CNS prophylaxis. Induction therapy with prednisone and vincristine results in hematological remission in more than 90% of patients. Maintenance chemotherapy essentially involves administration of daily oral 6-mercaptopurine (6-MP) and weekly or bi-weekly MTX, whereas intensification therapy often includes daunomycin and L-asparaginase [1].


Medical Oncology | 1991

Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia

Riccardo Riccardi; Anna Lasorella; Rosa Laura Tartaglia; Anna Riccardi; Tiziana Servidei; Renato Mastrangelo

We measured 6-mercaptopurine levels in the cerebrospinal fluid and plasma of 15 children undergoing treatment for acute leukemia. Plasma and cerebrospinal fluid samples obtained by lumbar puncture were collected before, during, and after cranial irradiation in order to evaluate a possible change in blood-brain barrier permeability to orally administered 6-mercaptopurine. Considerable interpatient variability has been observed in both plasma and cerebrospinal fluid 6-mercaptopurine levels. No statistical differences in the 6-mercaptopurine cerebrospinal fluid levels under the three different conditions could be detected. Our data suggest that cranial irradiation does not significantly influence the cerebrospinal fluid levels.


Medical and Pediatric Oncology | 1995

Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up-front" study.

Renato Mastrangelo; Anna Lasorella; Riccardo Riccardi; Cesare Colosimo; Antonio Iavarone; Assunta Tornesello; Stefano Mastrangelo; Giampiero Ausili-Cefaro; Concezio Di Rocco


Medical and Pediatric Oncology | 1986

Prognostic relevance of clinical pharmacology of antileukemic drugs.

Riccardo Riccardi; Anna Lasorella; Renato Mastrangelo


Archive | 2001

Methods for diagnosing and treating pediatric neoplasms

Antonio Iavarone; Anna Lasorella

Collaboration


Dive into the Anna Lasorella's collaboration.

Top Co-Authors

Avatar

Renato Mastrangelo

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Riccardo Riccardi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Cesare Colosimo

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Anna Riccardi

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Assunta Tornesello

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Tiziana Servidei

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Pietro Ferrara

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Riccardo Riccardi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonio Iavarone

The Catholic University of America

View shared research outputs
Researchain Logo
Decentralizing Knowledge